The investment bank gave Exact Sciences' shares a price target of $30, and said it expects higher uptake of the Cologuard test and an increase in payor contracts.
The investment bank also cited challenges for Illumina in penetrating the clinical diagnostics markets and driving physician adoption of its tests.
The investment bank noted increased traction for Invitae's test, a "massive" market opportunity, and potential clinical and payor adoption of the firm's technology.
The investment bank said the quick approval by the FDA for T2 Bio's platform and Candida test could signal high interest for the product in the medical community.
The downgrade follows Roche's proposed bid to acquire a majority stake in the company.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligences for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.